FDA warns of rare vision-loss side effect from GLP-1 drugs
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.
Watch CBS News
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.
Health and Human Services Secretary Robert F. Kennedy Jr. took steps Wednesday that could open up access to certain unapproved peptide drugs that are being promoted for wellness.
Growing usage of GLP-1 drugs for weight loss is reshaping how consumers shop for food and clothes, according to consulting firm EY-Parthenon.
The FDA has warned a major compounding pharmacy that it violated federal law by making copies of blockbuster weight-loss drugs in "inordinate amounts."
Here's how weight-loss drugs like Ozempic and Wegovy could reduce worker illness and save companies money.
The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's.
For the first time, Medicare will cover GLP-1 drugs prescribed solely for weight loss for eligible beneficiaries at a $50 monthly copay.
As obesity rates among Americans drop and weight loss drugs lead to a slimmer society, airlines could save on fuel costs, according to a recent analysis.
FDA-approved semaglutide drug is the first GLP-1 pill for weight loss available in the U.S., according to drugmaker Novo Nordisk.
The Food and Drug Administration has approved a pill version of the weight-loss drug Wegovy.
A clinical study into weight loss drugs for pets just launched, with results from the trial expected by next summer.
The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month in some cases, officials said.
As more Americans turn to weight loss drugs, the U.S. adult obesity rate is declining, according to new survey data from Gallup.
Tennis legend Serena Williams is sharing her journey with weight loss drugs, saying she's lost 31 pounds in 8 months using GLP-1s.
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.
A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their children with Prader-Willi syndrome deal with unrelenting hunger.
Late last year, South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But access remains limited.
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Body Mass Index, or BMI, has long been criticized as an unreliable method for measuring obesity — and now a group of experts is sharing new recommendations for how to use it.
This may be the first Thanksgiving for millions of Americans who are on GLP-1 agonists like Ozempic, Zepbound or Wegovy.
About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to several obesity experts.
Record demand for Ozempic, Wegovy and other weight loss drugs is fueling a surge of dangerous knockoffs.
Drugs like Mounjaro and Ozempic, which many use for weight loss, may also help patients suffering from addiction, according to a new study.
The latest CDC survey found 4 in 10 adults in the U.S. were obese. A map shows the states with the highest and lowest rates.
